Friday, February 10, 2017 2:25:18 PM
This from The Fly (free comments)
08:45 Intercept CEO says OCA phase 3 trial changes make positive results more likely Intercept Pharmaceuticals CEO Mark Pruzanski said the company continues to be confident on both endpoints, but now only needs to hit on either NASH resolution or fibrosis improvement for the trial to be considered a success. Read more at: http://thefly.com/landingPageNews.php?id=2503483
Read more at:
http://thefly.com/landingPageNews.php?id=2503483
Intercept analyst commentary at Leerink Leerink 'not convinced' Intercept trial changes up chance of success. Leerink analyst Joseph Schwartz says he's "not convinced" the endpoint changes raise the probability of success for Intercept Pharmaceuticals' obeticholic acid. It is discouraging that enrolling the 1,400 patient cohort was unattainable in a timely manner, Schwartz tells investors in a research note. Read more at: http://thefly.com/landingPageNews.php?id=2503649
Read more at:
http://thefly.com/landingPageNews.php?id=2503649
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM